(NASDAQ: BDTX) Black Diamond Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.81%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 35.93%.
Black Diamond Therapeutics's earnings in 2026 is $22,367,000.On average, 11 Wall Street analysts forecast BDTX's earnings for 2026 to be -$36,813,751, with the lowest BDTX earnings forecast at -$50,528,678, and the highest BDTX earnings forecast at -$11,429,106. On average, 10 Wall Street analysts forecast BDTX's earnings for 2027 to be -$57,122,613, with the lowest BDTX earnings forecast at -$75,231,587, and the highest BDTX earnings forecast at -$30,076,594.
In 2028, BDTX is forecast to generate -$45,464,352 in earnings, with the lowest earnings forecast at -$74,670,157 and the highest earnings forecast at -$22,256,679.